The top 5 OncLive TV videos of the week cover insights in essential thrombocythemia, CML, pancreatic cancer, myelofibrosis, and chronic neutropenia.
Commentary|Articles|August 26, 2025
4 Ways Oncologists Use Social Media to Debunk Myths and Dispel Misinformation
Author(s)Ashley Chan
Fact checked by: Chris Ryan
Eric K. Singhi, MD, and Shruti Patel, MD, discuss how they extend beyond the walls of their clinic to provide accurate cancer updates on social media.
Advertisement
Advertisement
In 2025, social media platforms have become an invaluable tool to learn something quickly, connect with colleagues, and stay abreast with the latest news and trends across specialties. However, using these tools remains a double-edged sword, especially with the spread of misinformation, which is why Eric K. Singhi, MD, and Shruti Patel, MD, have taken it upon themselves to challenge misinformation about cancer on social media.
Related to this article
The FDA approved camizestrant for ESR1-mutated breast cancer, cleared ropeginterferon alfa-2b for essential thrombocythemia, and more.
Did you catch all of this week's top oncology news? Test your knowledge with OncLive's Weekly News Quiz.
Daraxonrasib produced a 42% overall response rate and 16.0-month median OS in previously treated RAS-mutant NSCLC in a phase 1/2 trial.
Ivonescimab significantly improved OS vs pembrolizumab at a prespecified interim analysis of the HARMONi-2 trial in first-line PD-L1–positive NSCLC.
A pharmacokinetic sub-study found that TAMP-mediated gemcitabine reduced systemic drug exposure in patients with locally advanced pancreatic cancer.
Here is your cheat sheet to all therapeutic options that were cleared by the FDA in August 2026 spanning tumor types.
Faculty convened at an OncLive Scientific Interchange and Workshop to discuss optimizing first-line treatment selection and second-line sequencing in EGFR-mutated NSCLC.
Advertisement
Advertisement